11:29 AM EDT, 08/19/2024 (MT Newswires) -- Jaguar Health ( JAGX ) said Monday Hong Kong's Intellectual Property Department has issued a new patent to its family firm, Napo Pharmaceuticals, for methods for treating short bowel syndrome, bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, its prescription drug.

"We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said CEO Lisa Conte.

Price: 1.28, Change: +0.01, Percent Change: +0.47